PubMed:25054547 / 143-324 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T2","span":{"begin":0,"end":181},"obj":"Sentence"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-entities","denotations":[{"id":"10157","span":{"begin":0,"end":32},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10158","span":{"begin":63,"end":68},"obj":"DiseaseOrPhenotypicFeature"},{"id":"10159","span":{"begin":86,"end":102},"obj":"ChemicalEntity"},{"id":"10160","span":{"begin":104,"end":117},"obj":"ChemicalEntity"},{"id":"10161","span":{"begin":121,"end":131},"obj":"ChemicalEntity"},{"id":"10162","span":{"begin":136,"end":144},"obj":"OrganismTaxon"},{"id":"10163","span":{"begin":171,"end":175},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A5","pred":"db_id","subj":"10157","obj":"MESH:C537417"},{"id":"A6","pred":"db_id","subj":"10158","obj":"MESH:D001049"},{"id":"A7","pred":"db_id","subj":"10160","obj":"MESH:D013390"},{"id":"A8","pred":"db_id","subj":"10161","obj":"MESH:D000077590"},{"id":"A9","pred":"db_id","subj":"10162","obj":"NCBITaxon:9606"},{"id":"A10","pred":"db_id","subj":"10163","obj":"NCBIGene:590"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":0,"end":32},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0015270"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T3","span":{"begin":0,"end":21},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":86,"end":92},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":171,"end":175},"obj":"GeneOrGeneProduct"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T6","span":{"begin":0,"end":21},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":86,"end":92},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":93,"end":102},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":154,"end":163},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":171,"end":175},"obj":"GeneOrGeneProduct"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T2","span":{"begin":0,"end":32},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":63,"end":68},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"originalLabel","subj":"T2","obj":"C537417"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D001049"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T2","span":{"begin":0,"end":21},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":171,"end":175},"obj":"GeneOrGeneProduct"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":0,"end":32},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0015270"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T2","span":{"begin":0,"end":32},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":63,"end":68},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"ID:","subj":"T2","obj":"C537417"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D001049"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T2","span":{"begin":0,"end":32},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":63,"end":68},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"#label","subj":"T2","obj":"C537417"},{"id":"A3","pred":"#label","subj":"T3","obj":"D001049"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T3","span":{"begin":0,"end":32},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":86,"end":102},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":104,"end":117},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":121,"end":131},"obj":"ChemicalEntity"}],"attributes":[{"id":"A3","pred":"ID:","subj":"T3","obj":"C537417"},{"id":"A4","pred":"ID:","subj":"T4","obj":"ChemicalEntity"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D013390"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_45652"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D000077590"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":136,"end":144},"obj":"OrganismTaxon"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T7","span":{"begin":121,"end":131},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":104,"end":117},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":86,"end":102},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":0,"end":32},"obj":"ChemicalEntity"},{"id":"T53614","span":{"begin":171,"end":175},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":0,"end":21},"obj":"GeneOrGeneProduct"},{"id":"T85129","span":{"begin":63,"end":68},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T57186","span":{"begin":0,"end":32},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T32204","span":{"begin":136,"end":144},"obj":"OrganismTaxon"}],"attributes":[{"id":"A7","pred":"ID:","subj":"T7","obj":"D000077590"},{"id":"A6","pred":"ID:","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_45652"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D013390"},{"id":"A4","pred":"ID:","subj":"T4","obj":"ChemicalEntity"},{"id":"A3","pred":"ID:","subj":"T3","obj":"C537417"},{"id":"A4639","pred":"#label","subj":"T85129","obj":"D001049"},{"id":"A44419","pred":"#label","subj":"T57186","obj":"C537417"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T2","span":{"begin":0,"end":181},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":181},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":63,"end":68},"obj":"HP_0002104"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"PubCasesHPO","denotations":[{"id":"AB1","span":{"begin":63,"end":68},"obj":"HP:0002104"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}

{"project":"PubCasesORDO","denotations":[{"id":"AB1","span":{"begin":0,"end":32},"obj":"ORDO:132"}],"namespaces":[{"prefix":"ORDO","uri":"http://www.orpha.net/ORDO/Orphanet_"}],"text":"Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene."}